Breaking News, Collaborations & Alliances

Sony, Astellas Partner to Discover a Novel ADC Platform in Oncology

Collaborative research will leverage Sony's polymeric materials to achieve high-DAR ADC.

Sony Corporation and Astellas Pharma Inc. entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC) platform in oncology based on Sony’s unique polymeric material, KIRAVIA Backbone. ADCs are expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells. The technology to create linkers which conjugates antibodies and drugs, is considered t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters